5- ((5- bromo- 1H- indol- 3- yl)methylene)- 3- (4- chlorobenzyl)thiazolidine- 2,4- dione

structure in first source

Also Known As:

LYSO-7

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Thiazolidinediones: 2250
        5-((5-bromo-1H-indol-3-yl)methylene)-3-(4-chlorobenzyl)thiazolidine-2,4-dione: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 5-((5-bromo-1H-indol-3-yl)methylene)-3-(4-chlorobenzyl)thiazolidine-2,4-dione: 4
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - Thiazolidinediones: 2250
      - 5-((5-bromo-1H-indol-3-yl)methylene)-3-(4-chlorobenzyl)thiazolidine-2,4-dione: 4

Experts

1.	Pitta, Ivan R: 2 articles (09/2021 - 08/2015)
2.	Farsky, Sandra H P: 2 articles (09/2018 - 01/2013)
3.	Santin, José Roberto: 2 articles (09/2018 - 01/2013)
4.	da Rocha Pitta, Ivan: 2 articles (09/2018 - 01/2013)
5.	Abdalla, Dulcinéia S P: 1 article (09/2021)
6.	Garcia, Giani M: 1 article (09/2021)
7.	Grabe-Guimarães, Andrea: 1 article (09/2021)
8.	Mosqueira, Vanessa C F: 1 article (09/2021)
9.	Richard, Sylvain: 1 article (09/2021)
10.	Roy, Jérôme: 1 article (09/2021)

Related Diseases

1.	Inflammation (Inflammations) 08/01/2015 - "Altogether, our data show that LYSO-7 possesses anti-inflammatory properties and that treatment with this TZD attenuates atherosclerosis progression in LDLr(-/-) mice by modulating lipid metabolism and inflammation. " 08/01/2015 - "In this study, we evaluated the biological activity of LYSO-7, a new indole-thiazolidine, on PPAR activation, inflammation and atherogenesis using a gene reporter assay, lipopolysaccharide (LPS)-activated RAW 264.7 cell culture, and a low-density lipoprotein receptor knockout (LDLr(-/-)) mouse model of atherosclerosis. " 09/01/2018 - "Here, we investigated the mechanisms of action of a ligand of the three isoforms of peroxisome proliferator-activated receptors (PPAR; (5Z)-5-[(5-bromo-1H-indole-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione), dubbed LYSO-7, on neutrophils activated by N-formyl-l-methionyl-l-leucyl-l-phenylalanine (fMLP), an agonist of G-protein coupled receptors (GPCRs) that binds to membrane-formylated peptide and activates intracellular inflammation pathways. "
2.	Atherosclerosis 08/01/2015 - "Thus, LYSO-7 shows potential as a new drug candidate for the treatment of atherosclerosis. " 08/01/2015 - "Altogether, our data show that LYSO-7 possesses anti-inflammatory properties and that treatment with this TZD attenuates atherosclerosis progression in LDLr(-/-) mice by modulating lipid metabolism and inflammation. " 08/01/2015 - "In addition, treatment with LYSO-7 reduces the development of atherosclerosis in LDLr(-/-) mice, improves the lipid profile, blood glucose levels, and downregulates CD40 and CD40L expression without affecting the body weight of the animals. " 08/01/2015 - "In this study, we evaluated the biological activity of LYSO-7, a new indole-thiazolidine, on PPAR activation, inflammation and atherogenesis using a gene reporter assay, lipopolysaccharide (LPS)-activated RAW 264.7 cell culture, and a low-density lipoprotein receptor knockout (LDLr(-/-)) mouse model of atherosclerosis. "
3.	Cardiotoxicity 09/20/2021 - "We investigated the cardiotoxicity of free Lyso-7 in vitro (4.5-450 nM), and Lyso-7 loaded in polylactic acid nanocapsules (NC) in vivo (Lyso-7-NC, 1.6 mg/kg). "
4.	Weight Loss (Weight Reduction) 01/01/2013 - "In addition, LYSO-7 may induce less toxicity, as 28 days of oral treatment did not induce weight loss, as detected in pioglitazone treated mice. "
5.	Body Weight (Weight, Body) 08/01/2015 - "In addition, treatment with LYSO-7 reduces the development of atherosclerosis in LDLr(-/-) mice, improves the lipid profile, blood glucose levels, and downregulates CD40 and CD40L expression without affecting the body weight of the animals. "

Related Drugs and Biologics

1.	Thiazolidines
2.	Peroxisome Proliferator-Activated Receptors (PPAR)
3.	indole
4.	LDL Receptors (LDL Receptor)
5.	Lipopolysaccharides
6.	Nanocapsules
7.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
8.	CD40 Ligand (CD40L)
9.	Protein Isoforms (Isoforms)
10.	Phenylalanine (L-Phenylalanine)